凱萊英(002821.SZ)披露定增報告書:高瓴獲配10億元的股份
格隆匯 10 月 12日丨凱萊英(002821.SZ)披露非公開發行股票發行情況報告書暨上市公告書,根據投資者認購情況,此次非公開發行股票數量為1017.8731萬股,募集資金總額約23.11億元,未超過公司董事會、股東大會審議通過並經中國證監會核准的發行數量。
發行人和主承銷商根據投資者申購報價情況,嚴格按照認購邀請書中確定發行價格、發行數量及發行對象的程序和原則,確定此次非公開發行價格為227元/股。
此次發行最終獲配對象為9名,此次發行配售的具體情況如下:


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.